Onconic Therapeutics announced on Monday that its groundbreaking research on a new drug candidate has been selected for oral presentation at ObesityWeek 2026, scheduled for November in Washington D.C. The abstract has been accepted as part of the conference’s cutting-edge research program.
This presentation is particularly significant as it showcases the first official research outcomes for a novel drug candidate, following in the footsteps of Nesuparib. Onconic Therapeutics plans to use this conference as a launchpad to accelerate the research and development of its next-generation drug pipeline.
Building on its success with JAQBO (zastaprazan), a self-developed and commercialized treatment for gastroesophageal reflux disease, Onconic Therapeutics is now advancing its cancer drug candidate, Nesuparib. This innovative compound functions as a dual inhibitor, simultaneously targeting PARP and Tankyrase, both crucial in cancer cell DNA repair processes. Nesuparib is currently being developed to combat multiple cancer types.
ObesityWeek’s rigorous selection process evaluates research abstracts based on their significance, novelty, methodology, results, and conclusions. The importance criteria include the research’s originality and its potential to advance the field’s theoretical framework and knowledge base. Onconic’s research successfully met these stringent standards, earning both abstract acceptance and an oral presentation slot.
Due to the conference’s embargo policy, Onconic Therapeutics is currently unable to disclose the pipeline name, specific research details, or results of the new drug candidate. The company plans to release this information progressively in accordance with the conference schedule.
A spokesperson for Onconic Therapeutics emphasized the significance of this development, stating that this research leverages the proprietary artificial intelligence (AI) based analysis and screening system to explore and validate new possibilities for the candidate substance. The introduction of this next-generation drug candidate, which it believes has global blockbuster potential, marks a pivotal moment for the company.
